LYP: therapies and results
| Therapy . | References . | No. of patients . | CR, no. (%) . | Relapse rate, no. (%) . |
|---|---|---|---|---|
| PUVA | 59,60,62,,,,,–68,75 | 19 | CR: 5/19 (26) | 16/19 (84) |
| PR: 13/19 (68) | ||||
| NR: 1/19 (5) | ||||
| Systemic methotrexate | 61,72,,,,,,,,–81 | 79 | CR: 27/79 (34) | 47/75 (63) |
| PR: 52/79 (66) | ||||
| NR: 1/79 (0.1) | ||||
| Topical steroids | 63,84,,,,,–90 | 25 | CR: 3/25 (12) | NA |
| PR: 22/25 (88) |
| Therapy . | References . | No. of patients . | CR, no. (%) . | Relapse rate, no. (%) . |
|---|---|---|---|---|
| PUVA | 59,60,62,,,,,–68,75 | 19 | CR: 5/19 (26) | 16/19 (84) |
| PR: 13/19 (68) | ||||
| NR: 1/19 (5) | ||||
| Systemic methotrexate | 61,72,,,,,,,,–81 | 79 | CR: 27/79 (34) | 47/75 (63) |
| PR: 52/79 (66) | ||||
| NR: 1/79 (0.1) | ||||
| Topical steroids | 63,84,,,,,–90 | 25 | CR: 3/25 (12) | NA |
| PR: 22/25 (88) |
NR indicates no response; and NA, not available.